A critical comparison between the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines (Rename)  by Coelho, Helena Lutéscia L. et al.
J Pediatr (Rio J). 2013;89(2):171−178
0021-7557      © 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. 
http://dx.doi.org/10.1016/j.jped.2013.03.004
www.jped.com.br
☆Please, cite this article as: Coelho HL, Rey LC, de Medeiros MS, Barbosa RA, Fonseca SG, da Costa PQ. A critical comparison between 
the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines (Rename).  
J Pediatr (Rio J). 2013;89:171−8.
* Corresponding author.
E-mail: helenalutescia@yahoo.com.br (H.L.L. Coelho).
ORIGINAL ARTICLE
A critical comparison between the World Health Organization list 
of essential medicines for children and the Brazilian list  
of essential medicines (Rename)☆
Helena Lutéscia L. Coelhoa,*, Luís Carlos Reyb, Marina S.G. de Medeirosc,  
Ronaldo A. Barbosad, Said G. da Cruz Fonsecae, Patricia Q. da Costaf
aPhD in Pharmacology, Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal do Ceará (UFC), 
Fortaleza, CE, Brazil 
bPhD in Pediatrics, Departamento de Saúde Materno-Infantil, UFC, Fortaleza, CE, Brazil
cPharmacist. MSc Candidate in Pharmaceutical Sciences, UFC, Fortaleza, CE, Brazil
dPharmacist, UFC, Fortaleza, CE, Brazil
eMSc in Pharmaceutical Sciences, Programa de Pós-graduação em Desenvolvimento e Inovação Tecnológica  
em Medicamentos, UFC, Fortaleza, CE, Brazil
fPhD in Public Health. Professor, Centro Universitário Estácio – Faculdades Integradas do Ceará, Fortaleza, CE, Brazil
Received 8 May 2012; accepted 29 August 2012
KEYWORDS
Newborn;
Infant;
Child;
Pharmaceutical 
preparations;
Health public policy;
Drugs, essential
Abstract 
Objective: To perform a critical comparison between the Brazilian national essential 
medicines list (Rename, 2012) with the list of essential medicines for children (LEMC, 
2011) of the World Health Organization (WHO), regarding the differences among drugs 
and formulations listed for children. 
Methods: The LEMC drugs were classified into four categories: 1) absent in Rename; 
2) included in Rename but without any formulation suitable for children; 3) listed in 
Rename only in some formulations; 4) present in Rename in all formulations. The missing 
formulations were analyzed by therapeutic group. Alternatives present in Rename were 
searched.
Results: From the 261 drugs of interest on the LEMC, 30.3% are absent from Rename, 
11.1% are in Rename but without any pediatric formulation, and 32.2% are present in 
some but not all formulations listed in LEMC. Considering all formulations items listed in 
the LEMC (n = 577), 349 are missing from Rename, of these 19.6% due to their strength, 
and 18.5% due to the the dosage form. Useful formulations specific for neonatal care, 
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Uma comparação crítica entre a Lista de Medicamentos Essenciais para Crianças da 
Organização Mundial de Saúde e a Relação Nacional de Medicamentos Essenciais 
(Rename)
Resumo 
Objetivo: Realizar uma comparação crítica entre a Relação Nacional de Medicamentos 
Essenciais (Rename, 2012) e a Lista de Medicamentos Essenciais para Crianças (LMEC, 
2011) da Organização Mundial de Saúde (OMS), com relação às diferenças entre os medi-
camentos e as formulações listadas para crianças. 
Métodos: Os medicamentos da LMEC foram classificados em quatro grupos: 1) não cons-
tam na Rename; 2) constam na Rename, porém sem qualquer formulação adequada para 
crianças; 3) listados na Rename apenas com algumas formulações; 4) constam na Rename 
em todas as formulações. As formulações que faltam foram analisadas por grupos tera-
pêuticos. As alternativas presentes na Rename foram pesquisadas.
Resultados: Dos 261 medicamentos de interesse listados na LMEC, 30,3% não estão pre-
sentes na Rename, 11,1% estão na Rename, mas sem qualquer formulação pediátrica, 
e 32,3% estão presentes em algumas, mas não todas as formulações listadas na LMEC. 
Considerando todos os itens de formulações listados na LMEC (n = 577), 349 não constam 
na Rename, desses, 19,6% devido à intensidade de dosagem, e 18,5% devido à forma 
farmacêutica. Faltam formulações úteis específicas para cuidado neonatal, trato respi-
ratório e sistema nervoso central, anti-infecciosos, entre outros grupos.
Conclusão: A ausência de formulações adequadas à idade de medicamentos essenciais 
para crianças no Brasil inclui importantes grupos terapêuticos e medicamentos indispen-
sáveis para quadros clínicos graves. Alguns desses produtos são encontrados no mercado 
farmacêutico brasileiro, porém não existem em unidades públicas; outros poderiam ser 
produzidos por laboratórios nacionais com interesse comercial ou estimulados por uma 
política governamental específica, como é feito em outros países.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.  
Introduction
The concept of essential medicines is globally accepted 
as a powerful means of promoting health equity and is 
instrumentalized by a reference list. By definition, essential 
medicines are those that satisfy the priority health care 
needs of the population.1 The elaboration of a list of 
essential medicines for children (LEMC) was conducted to 
correct an injustice that prevailed for 40 years, since the 
World Health Organization (WHO) general list of essential 
medicines did not sufficiently contemplate the treatment 
needs of children. These needs refers to the specificities of 
children as an heterogeneous group in terms of the physical, 
metabolic, and psychological processes peculiar to this age 
group, and to pharmaceutical aspects of formulations that 
are critical for the administration in children, such as tablet 
size, volume of parenteral medicine, and palatability of 
pediatric oral medications.2-4
The LEMC embodies a model list to be adapted by 
nations according to their needs and circumstances. It is a 
dynamic tool, reviewed and updated periodically by ad hoc 
committees, as has occurred with the main List of Essential 
Medicines for 40 years. The LEMC, even in its third version 
(2011), remains incomplete and certainly unsatisfactory 
due to a lack of appropriate medicines for children in the 
world. The process of selecting essential medicines is based 
on worldwide-validated procedures established on the 
evaluation of existing evidence about efficacy and safety of 
use, convenience for the patients, and compatibility of the 
costs with the resources of the patients or the community.5 
respiratory tract, central nervous system, and anti-infectives, among other groups, are 
missing.
Conclusion: The lack of age-appropriate formulations of essential medicines for children 
in Brazil includes important therapeutic groups and indispensable drugs for severe clinical 
conditions. Some of these products exist in the Brazilian pharmaceutical market, but not 
in public facilities; others could be produced by national laboratories with commercial 
interest or stimulated by a specific governmental policy, as in other countries.
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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For pediatric medicines, this evaluation is limited by the 
scarcity of available evidence and of well-performed 
controlled clinical trials in children, by the limitations of 
the pharmacokinetic knowledge in different age groups, 
as well as by the scarcity of appropriate formulations for 
subgroups in different stages of physiological development, 
e.g. preterm neonates, full term neonates, infants and 
toddlers, and older children and adolescents.6-9
Brazil has a national drug policy defined by law10 that 
includes the national list of essential medicines (Relação 
Nacional de Medicamentos Essenciais – Rename) as a tool 
for its implementation. This instrument is a general list 
that orients the availability of medicines in the health system 
nationwide. In the latest versions, Rename has progressively 
been including medicines and drug formulations for pediatric 
use.11-13 Nevertheless, recent studies demonstrate a lack of 
access to age-adapted formulations in public facilities, as 
well as the inexistence of some necessary formulations in 
the Brazilian pharmaceutical market.14-20
The aim of the present study is to critically compare 
the Rename 2012 with the LEMC 2011, outlining the lack 
of medicines and formulations for children in the Brazilian 
reference list to discuss the need for a specific governmental 
policy to stimulate this area.
Methods
The composition of the Rename 201213 was compared with 
the composition of the LEMC 201121 in terms of the presence 
of medicines and formulations suitable for children, by 
building a spreadsheet using Microsoft Excel 2007® software. 
Two trained reviewers were assigned to compare the lists 
and build the spreadsheet with the supervision of a clinical 
pharmacist experienced in pediatric pharmacy.
A pharmaceutical presentation or formulation was 
considered by definition as a drug product in a determined 
dosage form and strength. Thus a drug may be presented in 
more than one formulation. This means that, for instance, 
tablets, oral dispersible tablets, scored tablets, capsules, 
cream, ointment, injectable, powder for injectable, as 
well different strengths of a drug, are considered different 
formulations. This analysis is justified on some specific 
characteristics of formulations that are crucial to facilitate 
the administration and to promote safe and effective use 
in children.2,3
The products were classified in four categories, depending 
on the presence or absence of the drug or its pediatric 
formulation in Rename. The categories are described in 
“Results”. Additionally, for every formulation absent in 
Rename, it was verified whether this absence was related to 
the strength of the active ingredient or to the dosage form. 
The combinations of active ingredients such as “lamividine 
+ zidovudine” were considered as distinct from formulations 
of the components separately. The adopted classification of 
drugs into therapeutic classes was the same as in the WHO 
list. An analysis was undertaken in order to identify which 
therapeutic classes are more affected by the absence of 
formulations for children in Rename.
Furthermore, the formulations present in Rename were 
searched for pediatric indication in the ANVISA package 
inserts compendium, available online (www.anvisa.gov) 
and reversely identified in LEMC 2011.
The study protocol was approved by the Ethics Committee 
of the Hospital São José, Fortaleza, Brazil.
Results
In the LEMC 2011, there are 272 different drugs or fixed-
dose combinations. For analysis purposes, 11 drugs that did 
not correspond to the epidemiological needs in Brazil were 
excluded from the comparison, among them the Japanese 
encephalitis vaccine and Pentamidine, a drug used in 
the treatment of West African trypanosomiasis (T. brucei 
gambiensis) and in rare cases of Pneumocystis jirovecii 
pneumonia (PCP) in AIDS patients allergic to cotrimoxazole/
trimethoprim. The range of analysis comprised the remaining 
261 drugs, considered essential for children in Brazil. 
From these 261 drugs found in LEMC 2011, 81 (31.0%) 
were completely absent from the Brazilian list published 
in 2012 and classified as category 1; category 2 comprises 
the 28 (10.7%) drugs present in Rename but without any 
suitable formulation for child use; in category 3, the 84 
(32.2%) drugs present in Rename at least in one formulation 
included in LEMC; and category 4 comprises 68 (26.1%) drugs 
present in Rename in all pediatric formulations existing in 
LEMC. 
Regarding pharmaceutical preparations, these 261 
selected essential drugs are presented in 577 distinct 
formulations in LEMC, 350 of which (60.7%) are absent from 
the Rename list: 113 in terms of strength of the preparation 
(19.6%), 106 in terms of dosage form (18.4%), and 131 in 
terms of absence of the active principle (22.7%). 
The formulations corresponding to the groups “diagnostic 
agents” and “ear, nose, and throat conditions in children” 
are completely absent from the Brazilian list. The 
categories “vitamins and minerals”, “muscle relaxants and 
cholinesterase inhibitors”, “specific medicines for neonatal 
care”, “anticonvulsants/antiepileptics” and “diuretics” 
have respectively 88.9%, 87.5%, 80.0%, 76.9%, and 75.0% of 
their formulations missing in Rename. 
Among the anti-infective medicines, at least 52.4% 
of the formulations of each therapeutic subgroup are 
lacking, mainly in the subgroups “anthelminthic” (78.6%), 
“antifungal” (73.3%), and “antibacterial medicines” (57,6%). 
In the “antibacterials” subgroup 64.0% of the subsection 
“antituberculosis medicines” is missing from the Rename. 
In the “antiprotozoal” subgroup, both “antitrypanossomal” 
and “antileishmaniasis” subsections have 75.0% of their 
formulations absent, and in the subsection “antimalarial” 
62.5% of the formulations are absent from Rename 2012.
Tables 1, 2, and 3 discriminate the missing formulations 
in some relevant therapeutic classes. In these tables, 
therapeutic alternatives existent in Rename 2012 in the 
same subgroups are described as drugs or formulations 
that are absent in LEMC 2011. As explained in the Methods 
section, Rename does not present the therapeutic 
indication of drugs; this information was researched in the 
online package inserts compendium. In the therapeutic 
group “specific medication for neonatal care”, caffeine 
citrate, prostaglandin E and ibuprofen formulations were 
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withdrawn, letting this population without appropriate 
alternatives for critical conditions. Among medicines acting 
on the respiratory tract, only one formulation is missing, 
salbutamol sulfate 50 ug/mL in 5mL ampoule, and Rename 
presents more alternatives for asthma treatment than LEMC. 
In the group “anticonvulsant and antiepileptics”, suitable 
dosage forms and variety of strengths for common drugs 
(e.g. carbamazepine, diazepam, lorazepam, phenytoin) 
are missing, but Rename has some useful presentations of 
phenobarbital and valproic acid. 
Discussion
The lack of medicine formulations suitable for children 
is a worldwide concern, taken into consideration in 
some developed countries, as well as multilaterally by 
organizations such as the WHO.22-34
The present study performed an inventory of the missing 
essential medicines in suitable formulations for children 
in Rename, using LEMC as a reference. Some of the drugs 
completely absent in Rename but present in LEMC have 
minimal or no importance for Brazilian children (such as 
miltefosine, used in American visceral leishmaniasis), but 
others are useful systemic antibiotics, such as vancomycin, 
ampicillin, and cloxacillin (or its equivalent oxacillin, widely 
used in Brazil). This was not an exhaustive quantitative or 
qualitative analysis regarding which drugs and formulations 
should be considered essential for Brazilian children, rather 
an attempt to describe the lack of drugs and formulations 
suitable for children as a relevant problem that deserves 
the attention of Brazilian health policy makers. It is well-
known that the absence of appropriate medicines and 
formulations for children (drugs duly studied in children, 
suitable dosage form, and strength) leads to unlicensed 
and off-label use of medicines and/or to the use of less 
safe or effective drugs.7,35 The lack of specific medication 
for neonatal treatment, as when comparing Rename to 
LEMC, forces the use of magistral or extemporaneous 
preparations, and sometimes the replacement of a drug by 
a more toxic substitute. The first is exemplified by the use 
of prepared caffeine citrate as respiratory stimulant, and 
the second by the use of indomethacin instead of ibuprofen 
for patent ductus arteriosus.36 Another example relative 
to neonates is the absence of ampicillin and gentamycin 
antimicrobials in Rename, which jeopardizes the adequate 
treatment of Enterococcus sp. and Listeria monocytogenes 
systemic infections.37 Such strategies are associated with 
Table 1 Missing formulations for neonatal care, respiratory tract, central nervous system, and their therapeutic alternatives 
present only in Rename.
Group Drug Formulations missing in Rename Therapeutic alternatives present  
   only in Rename
Specific medicines Caffeine citrate  Injection: 20 mg/mL − 
for neonatal care  Oral liquid (solution): 20 mg/mL
 Prostaglandin E Solution for injection (E1: 0.5 mg/mL − 
  in alcohol; E2: 1 mg/mL) 
 Ibuprofen Solution for injection: 5 mg/mL −
Medicines acting Salbutamol sulfate  Injection: 50 mcg/mL in Formoterol
on the respiratory  5-mL ampoule Inhalation powder: 12 mcg 
tract   Inhalation capsules: 12 mcg
   Formoterol + Budesonide 
   Inhalation powder: 6 mcg + 200 mcg
   Inhalation capsules: 6 mcg + 200 mcg 
Anticonvulsants/  Carbamazepine Tablet (chewable and scored):  
Antiepileptics  100 mg and 200 mg −
 Diazepam Rectal solution −
 Lorazepan Parenteral formulation −
 Phenobarbital  Oral liquid 3 mg/mL Phenobarbital
 Injection 200 mg/mL Oral liquid: 40 mg/mL 
   Injection: 100 mg/mL 
 Phenytoin  Capsule: 25 mg, 50 mg,  − 
 (sodium salt) and 100 mg  
  Tablet: 25 mg and 50 mg 
  Chewable tablet: 50 mg
 Valproic acid Oral liquid (solution): 40 mg/mL Valproic acid (sodium valproate) 
 (sodium valproate)
  Tablet: 100 mg Oral liquid: 50 mg/mL
  Tablet (enteric-coated): 200 mg Tablet or capsule: 250 mg
   Clonazepam 
   Oral solution: 2.5 mg/mL
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medication errors and adverse events, as suggested by 
several studies performed worldwide.16-18,38-40 In some 
therapeutic subgroups, as in the case of “medicines for 
asthma treatment”, more alternatives are present in 
Rename compared to LEMC, but there are critical issues. For 
example, the salbutamol solution for nebulization present 
in Rename is ten times stronger (500 mcg/mL) than that 
of LEMC (50 mcg/mL), increasing the possibility of errors. 
Furthermore, the inclusion of formoterol as a single drug 
is inconvenient, considering the recognized risk of using 
isolated long-acting beta2-agonists in asthma.41,42
In the case of the antiepileptic medicines, ethosuximide 
liquid formulation suitable for children was included in the 
Rename 2012, and phenytoin is present as oral solution 
and syrup of 50 mg/mL, but not in chewable tablet, or in 
25 mg and 50 mg tablets as in LEMC. In the “antifungals, 
antihelminthics, and antitrypanosomals” group, the reduced 
span of antihelmintic drugs in Rename is remarkable, and 
is inconsistent with the country’s reality. Distinctly from 
LEMC, pyrantel, niclosamide, and mebendazole are not 
available. Praziquantel is also present in 150 mg tablets 
in the LEMC, and niclosamide in chewable tablets. There 
is still a need in Rename for non-absorbable drugs for 
intestinal helminths. In the case of the antitrypanosomals, 
Rename is more complete, and includes benznidazole in 
12.5 mg tablets, a dosage not found in LEMC. 
Regarding antivirals and antiretrovirals, as a rule, 
Rename includes most of the available alternatives for 
antiretroviral therapy compatible with the need of the 
country, particularly highly active antiretroviral therapy, 
some in formulations suitable for children. However, 
there is a need for more oral solutions and more varied 
concentrations, as in the LEMC.
Some drugs absent from the Rename compared to the LEMC 
are important for Brazilian children, such as cloxacillin, a 
very specific antibiotic against mild to moderate infections 
by Staphylococcus aureus. This drug is often replaced in 
Brazil by cephalexin, a first-generation cephalosporin with 
a broader spectrum, effective in community-acquired 
Escherichia coli urinary tract infections. As cephalexin is 
frequently prescribed to treat Staphylococcus aureus skin 
infections, it induces an undesirable selective pressure over 
Escherichia coli, stimulating an increase in antimicrobial 
resistance. An example of inadequate formulation is the 
lack of isoniazid (INH) in liquid presentation of 50 mg/5 
mL strength in the Brazilian list. Rename only provides 
tablets of 100 mg of INH or combined INH/rifampin at 
75/150, 100/150, and 200/300mg tablets for children 
with tuberculosis. A difference in solution strength is also 
seen in the syrup concentration of prednisolone, which 
in LEMC is 5 mg/mL and in the Rename is 3 mg/mL. This 
lower concentration increases costs and reduces treatment 
compliance, as it requires a greater volume intake. 
The differences between Rename and LEMC shown in this 
study were expected, since the former is a list for current 
use in general medicine, and the opportunity to include 
comprehensive pediatric needs is therefore remote. The 
fact that many formulations present in the LEMC cannot 
be found in the Brazilian pharmaceutical market should 
restrict the possibility of their inclusion in a national list. 
However, it would be desirable that the Rename clearly 
expressed the need for pediatric medicines in Brazil to 
Table 2 Missing formulations and therapeutic alternatives present only in Rename: antifungals, anthelminthics, 
antitrypanosomal.
Group Drug Formulations missing in Rename Therapeutic alternatives present  
   only in Rename 
Antifungal Fluconazole Capsule: 50 mg Fluconazole
 Griseofulvin Capsule or tablet: 125 mg, 250 mg Capsule: 100 mg 
  Oral liquid: 25 mg/mL Itraconazole
 Nystatin  Lozenge: 100,000 UI Oral liquid: 10 mg/mL
  Oral liquid (suspension): 10 mg/mL
  Tablet: 100,000 UI, 500,000 UI
 Flucytosine Capsule: 250 mg
  Infusion: 2.5 g in 250 mL (10 mg/mL)
Anthelminthics Levamisole Tablet: 50 mg, 150 mg Albendazole
   Oral suspension: 40 mg/mL
 Mebendazole Tablet (chewable): 100 mg, 500 mg
 Niclosamide  Chewable tablet: 500 mg
 Pyrantel Oral liquid: 50 mg/mL
  Tablet (chewable): 250 mg
 Ivermectin  Tablet (scored): 3 mg, 6 mg Ivermectin
   Tablet: 6 mg 
 Oxamniquine Capsule: 250 mg
 Praziquantel  Tablet: 150 mg
Antitrypanosomal Nifurtimox Tablet: 30 mg, 120 mg, 250 mg Benznidazole
medicines   Tablet: 12.5 mg
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pharmaceutical companies and health authorities. Besides, 
some formulations missing in Rename, described in Tables 
1, 2, and 3, are already available in private Brazilian 
pharmacies, as sodium valproate enteric coated tablets, 
and pyrantel pamoate and mebendazole suspensions. It 
would be feasible in these cases to provide full access to 
these formulations at public health facilities if they were 
included in the Rename list. 
Another aspect to be highlighted is that almost 70% of 
the missing formulations are related to strength and dosage 
form, suggesting that no technical issues need to be solved, 
only the lack of commercial interest and marketing concerns. 
Presently, dosage forms suitable for use in children include 
a great variety, such as suspensions, syrups, solutions, 
concentrates, granules, sprinkles, powders, scored or 
crushable tablets, and the new fast dispersing dosages forms 
(films, fast-melts, ODTs, minitablets, chewable tablets), 
among others.43 The palatability of medicines is also a field 
of great research investment, and is recognized as one of the 
most crucial factors influencing adherence to therapeutic 
regimens, mainly in young children.3 These technological 
advances need to be incorporated into these products for the 
benefit of Brazilian children. It is well known that research, 
development, and production of pediatric medicines are 
not currently goals of the pharmaceutical industry, with the 
exception of medicines for common diseases such as mild 
infections and medicines for asthma. Therefore policymaker 
initiatives are crucial through financial or technical support 
for research and development,1 and industrial production 
of new formulations.7,22,26,27,33,34 Costa et al., in a review of 
medical literature and reports from Brazilian pediatricians, 
identified 126 formulations necessary in the country, a great 
proportion of them already present in other marketplaces 
abroad.14 As in the present study, the referred formulations 
included antimicrobials, anti-asthmatics, and analgesics, 
indispensable drugs for severe clinical conditions such 
as convulsive disorders (anticonvulsants), cardiovascular 
diseases, and tuberculosis, as well as drugs for vulnerable 
age groups such as neonates. 
To address the great number of pediatric formulations 
required to be included in the Rename, the elaboration 
of a specific list of essential medicines for children in 
Brazil appears to be a worthy solution. Such an instrument 
could be part of a broadened policy to stimulate the 
Table 3 Missing formulation and therapeutic alternatives present only in Rename: anti HIV drugs.
Group Drug Formulations missing in Rename Therapeutic alternatives present  
   only in Rename
Antiviral Aciclovir  Oral liquid: 40 mg/mL Darunavir 
 Didanosine  Buffered powder for oral liquid  Tablet: 150 mg, 300 mg 
  (solution): 100 mg, 167 mg, 250 mg  
  Capsule (unbuffered enteric-coated):  
  125 mg, 200 mg Fosamprenavir 
  Tablet (buffered chewable, dispersible):  Oral suspension: 50 mg/mL 
  25 mg, 50 mg, 100 mg, 150 mg, 200 mg  
 Emtricitabine Capsule: 200 mg Tipranavir 
  Oral liquid: 10 mg/mL Oral solution: 100 mg/mL
 Stavudine Capsule: 15 mg, 20 mg Zanamivir
 Zidovudine  Capsule: 250 mg Inhaling powder: 5 mg 
  Tablet: 300 mg
 Efavirenz  Capsule: 50 mg, 100 mg
 Atazanavir  Solid oral dosage form: 100mg
 Lopinavir + ritonavir  Capsule: 133.3 mg + 33.3 mg. 
 Ritonavir  Tablet (heat stable): 25 mg, 100 mg
 Lamivudine + Tablet: 150 mg + 200 mg + 30 mg
 nevirapine +  Tablet (dispersible): 30 mg + 50 mg + 6 mg;  
 stavudine 60 mg + 100 mg + 12 mg 
 Lamivudine +  Tablet: 30 mg + 50 mg + 60 mg;  
 nevirapine +  150 mg + 200 mg + 300 mg 
 zidovudine
 Lamivudine +  Tablet: 30 mg + 60 mg 
 zidovudine
 Ribavirin Injection for intravenous administration:  Solid oral dosage form:  
  800 mg, 1000 mg  200 mg, 400 mg, 600 mg
 Oseltamivir Oral powder: 12 mg/mL
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development and production of medicines for children in 
the country. As proposed by Beggs et al.,44 the development 
of a pediatric-specific essential medicines list potentially 
increases the awareness of the need for pediatric-specific 
medications and formulations, and highlights areas of 
priority where medications are lacking. Providing access 
to these formulations according to the need and promoting 
their rational use in children are concomitant challenges to 
be addressed by Brazilian health policies.
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